Pharma

Your Article Summary

See Latest Articles

CHMP Recommends Approval of New Indication for Enbrel as Treatment for Severe Psoriasis in Paediatric Patients
Corporate News Releases - The Healthcare Sales & Marketing Network, 11/24/08

The European Committee for Medicinal Products for Human Use (CHMP) announced its positive recommendation for the approval of Enbrel (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque psoriasis. If approved by the European Commission, following the Committee's recommendation, Enbrel will become the first biologic treatment indicated for severe psoriasis in children and adolescents. Enbrel is currently approved in the European Union for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing spondylitis, psoriatic arthritis, moderate to severe rheumatoid arthritis (RA) in adults, and polyarticular juvenile idiopathic arthritis (JIA) in children.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals